. Author manuscript; available in PMC: 2014 Mar 19.

Published in final edited form as: Mol Cancer Ther. 2012 Mar 12;11(5):1071–1081. doi: 10.1158/1535-7163.MCT-11-0852

Table I. Cross Validation of Protein Panel across NSCLC Tissue and Treatments.

Dose-dependent change in protein levels were measured by western blot (data shown in Figures S2 and S3) and are marked with (+) for increase, (-) for decrease, (N.C) for no change, and (~) for not detected. The cell lines have various sensitivities for gefitinib: A431, IC₅₀ = 40 - 80 nM; HCC827, 100 nM; H1650, 1 μM; H23, 8 μM; and H1975, 12 μM. Protein level changes of the panel of proteins after treatment with selective inhibitors of MAPK (PD 98059), AKT (LY294002), erlotinib (on-axis control), and paclitaxel (off-axis control) are shown.

Tissue	A431	HCC827	H1650	H23	H1975	A431	A431	A431	A431
gefitinib IC₅₀ [nM]	0.5	0.1	1.0	8.0	12.0
Treatment	gefitinib	gefitinib	gefitinib	gefitinib	gefitinib	AKT (A6730)	MAPK (PD98059)	erlotinib	paclitaxel
BAG4	+	N.C.	N.C.	+	N.C.	+	N.C.	+	N.C.
CAD17	+	+	+	+	N.C.	N.C.	+	+	N.C.
CBFB	+	+	+	N.C.	N.C.	+	N.C.	+	N.C.
Claudin 1	+	N.C.	+	N.C.	N.C.	+	+	+	N.C.
ELAVL-1	+	+	+	N.C.	N.C.	N.C.	N.C.	+	N.C.
EpCAM	+	+	+	N.C.	N.C.	N.C.	N.C.	+	N.C.
HSPG2	+	N.C.	+	N.C.	N.C.	N.C.	N.C.	+	N.C.
PDCD4	+	+	+	N.C.	N.C.	N.C.	+	+	N.C.
PRDX6	+	+	+	N.C.	N.C.	N.C.	+	+	N.C.
QARS	+	+	+	N.C.	~	+	N.C.	+	N.C.
S100A9	+	+	N.C.	N.C.	N.C.	N.C.	+	+	N.C.
SNX5	-	-	N.C.	N.C.	N.C.	N.C.	N.C.	-	N.C.
SERPINE1	+	+	+	N.C.	N.C.	N.C.	+	+	N.C.
TNFAIP2	+	N.C.	+	+	N.C.	+	N.C.	+	N.C.
TESTICAN2	+	+	N.C.	~	N.C.	N.C.	+	+	N.C.
TROP-2	+	+	+	N.C.	N.C.	N.C.	N.C.	+	N.C.